Gilead Sciences, Inc.
http://www.gilead.com
Already a Biomedtracker subscriber?
You have access to the full company record through your subscription
Want to become a subscriber?
Subscribers get more company details, updates, company financials and company products.
Questions?
Questions?
Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
Latest From Gilead Sciences, Inc.
Allogene Frustrated By FDA’s Delayed CAR-T Trial Review
Allogene hopes its off-the-shelf CAR-T can begin a potentially pivotal Phase II study by the end of this year but is frustrated by an “under-resourced and overworked FDA.”
Galecto Validates LOXL2 Targeting With Interim Myelofibrosis Phase II Success
The US biotech’s LOXL2 inhibitor candidate has reduced collagen fibrosis of the bone marrow in a small number of Phase II patients, helping validate a historically tricky approach attempted by few.
Merck & Co Resumes Islatravir HIV Studies After Safety Concerns, But Abandons PrEP Approach
After a nine-month US FDA-imposed pause, Merck is relaunching its studies of islatravir with a lower dose, while also abandoning its use in PrEP studies.
Dazodalibep Expands Horizons With Phase II Sjögren’s Syndrome Data
A Phase II trial of the anti-CD40 drug, which Horizon Therapeutics acquired in early 2021, met its primary endpoint in Sj
Company Information
- Industry
- Biotechnology
-
Pharmaceuticals
- Drug Delivery
- Specialty Pharmaceuticals
- Other Names / Subsidiaries
-
- Arresto Biosciences, Inc.
- Asegua Therapeutics, LLC
- Calistoga Pharmaceuticals, Inc.
- CGI Pharmaceuticals, Inc.
- CV Therapeutics, Inc.
- Cytopia Limited
- EpiTherapeutics
- Eximias Pharmaceutical Corporation
- Immunomedics, Inc.
- Myogen
- MYR GmbH
- Nimbus Apollo, Inc.
- Nexstar Pharmaceuticals
- Oligogen, Inc.
- Pharmasset, Inc.
- Triangle Pharmaceuticals
- YM BioSciences Inc. (YMI)
- Kite Pharma, Inc.
- Kite Pharma EU
- T-Cell Factory B.V. (TCF)
- Cell Design Labs, Inc.
- Asegua Therapeutics